Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide-based therapeutics designed to address severe neuromuscular and neurological diseases. The company operates within the biopharmaceutical and genetic medicine industries, with a core emphasis on improving the delivery and potency of RNA-targeting therapies. PepGen’s primary strategic focus is enabling more effective intracellular delivery of antisense oligonucleotides (ASOs) to tissues that have historically been difficult to treat, particularly muscle and the central nervous system.
Founded in 2018, PepGen was established to commercialize a proprietary peptide-conjugated oligonucleotide platform developed out of academic research. The company completed its initial public offering in 2022 and trades on the NASDAQ under the ticker PEPG. Since inception, PepGen has evolved from a platform-focused research company into a clinical-stage organization advancing multiple therapeutic candidates, with its lead programs targeting Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).
Business Operations
PepGen’s operations are centered on the development of its proprietary Enhanced Delivery Oligonucleotide (EDO) technology, which combines therapeutic oligonucleotides with cell-penetrating peptides to improve tissue uptake and intracellular delivery. The company generates no commercial product revenue and is currently dependent on research and development activities funded through equity financing. Its core business consists of preclinical research, clinical development, regulatory strategy, and manufacturing oversight conducted through third-party contractors.
The company’s lead clinical programs include PGN-EDO51, developed for Duchenne muscular dystrophy patients amenable to exon 51 skipping, and PGN-EDODM1, targeting the genetic cause of myotonic dystrophy type 1. PepGen conducts its clinical trials primarily in the United States and Europe, while relying on contract research organizations, contract development and manufacturing organizations, and academic collaborators to support development, testing, and regulatory compliance.
Strategic Position & Investments
PepGen’s strategic direction centers on establishing the EDO platform as a differentiated delivery technology capable of outperforming conventional antisense oligonucleotides in potency and tissue penetration. Growth initiatives are focused on advancing its neuromuscular disease pipeline through clinical proof-of-concept studies while expanding the applicability of the platform to additional neurological and rare genetic disorders.
The company has not completed any transformative acquisitions as of the most recent public disclosures, instead prioritizing internal research and selective collaborations. PepGen has invested heavily in platform validation, preclinical models, and early-stage clinical trials to support potential future partnerships with larger pharmaceutical companies. Its emerging technology focus remains squarely within next-generation RNA therapeutics and delivery systems, an area of active investment across the biotechnology sector.
Geographic Footprint
PepGen is headquartered in Cambridge, Massachusetts, a major biotechnology hub within the United States. Its primary operations, including research leadership, corporate management, and clinical strategy, are based in this region. The company benefits from proximity to academic institutions, clinical research centers, and a skilled biotechnology workforce.
While corporate operations are U.S.-based, PepGen maintains an international footprint through global clinical trial activities and vendor relationships. Clinical studies and regulatory interactions extend into Europe, and the company works with international contract manufacturers and research organizations, giving it operational exposure across North America and Europe without maintaining significant physical infrastructure outside the United States.
Leadership & Governance
PepGen is led by an executive team with experience in biotechnology, drug development, and rare disease commercialization. The leadership’s stated strategic vision emphasizes disciplined clinical execution, platform validation, and long-term value creation through differentiated delivery technology rather than rapid portfolio expansion. The company is governed by a board of directors with expertise spanning biopharmaceutical R&D, finance, and corporate governance.
Key executives include:
- James G. McArthur, PhD – President and Chief Executive Officer
- Kimi Iguchi, MD, PhD – Chief Medical Officer
- Jonathan Kranz, MD – Chief Development Officer
- Kris Elmore – Chief Financial Officer
- Kathy Krysztofiak – Chief Operating Officer